Elevated M2 activation and CD32b levels may contribute to tumor progression, suggesting the potential therapeutic relevance of CD32b inhibition in attenuating M2 macrophage polarization and exerting anti-tumor immunity. This evidence concerns the gene FCGR2B and neoplasm.